
Leyden Labs aims to help people live their lives to the fullest. Our platform targets commonalities of viral families to protect humanity from known and future viruses. Our portfolio of accessible intranasal product candidates may provide people with the freedom to immediately protect themselves from and prevent the spread of many variants of respiratory viruses, including ones in the influenza and coronavirus families. The Leyden Labs’ energetic team of world-renowned biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses. *Only jobs officially posted by Leyden Labs are valid job openings. We have become aware of scammers impersonating our company and actively recruiting candidates for positions. This is fraudulent activity. Check our job postings online and contact Leyden Labs directly at jobs@leydenlabs.com to verify the accuracy of any recruiter contacts.

Leyden Labs aims to help people live their lives to the fullest. Our platform targets commonalities of viral families to protect humanity from known and future viruses. Our portfolio of accessible intranasal product candidates may provide people with the freedom to immediately protect themselves from and prevent the spread of many variants of respiratory viruses, including ones in the influenza and coronavirus families. The Leyden Labs’ energetic team of world-renowned biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses. *Only jobs officially posted by Leyden Labs are valid job openings. We have become aware of scammers impersonating our company and actively recruiting candidates for positions. This is fraudulent activity. Check our job postings online and contact Leyden Labs directly at jobs@leydenlabs.com to verify the accuracy of any recruiter contacts.
Headquarters: Leiden, Netherlands
Core tech: Intranasal delivery of broadly neutralizing antibodies for mucosal protection
Lead program: PanFlu (CR9114) — intranasal broadly neutralizing antibody for influenza (licensed from Janssen)
Recent financing: $70M round announced Jan 9, 2025
Prevention of respiratory viral infections through mucosal immunity
2020
Biotechnology Research
$140M
Reported as closing a $140M Series B and bringing total capital to approximately $200M at that time.
$70M
Round announced to advance intranasal antibody programs with participation from Qiming, GV, Casdin and others.
€20M
Debt financing to support pandemic preparedness activities.
“Backed by leading life-science VCs and strategic investors including GV (Google Ventures), Casdin Capital, F-Prime Capital, ClavystBio (Temasek-backed), Polaris Partners, Qiming Venture Partners, Invus, SoftBank Vision Fund 2, Byers Capital, and public/backing from European institutions (EIB, EIC Fund, Invest-NL).”
| Company |
|---|